Chordia Therapeutics Inc is among a number of new Japanese bioventures born out of former research activities at Takeda Pharmaceutical Co. Ltd., but is now looking to blaze its own trail as it progresses a number of novel oncology assets.
The Fujisawa-based operation was formed in November 2017 around a portfolio of selected assets that originally came out of the Japan-based oncology discovery unit at Takeda,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?